Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
7 p, 740.6 KB Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) / Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ; Felip Font, Enriqueta (Universitat Autònoma de Barcelona) ; Matito, J (Institut d'Oncologia de la Vall d'Hebron) ; Mereu, Elisabetta (Universitat Pompeu Fabra) ; Navarro, A (Vall d'Hebron Institut d'Oncologia) ; Cedrés, S (Vall d'Hebron Institut d'Oncologia) ; Pardo Aranda, Núria (Universitat Autònoma de Barcelona) ; Martinez de Castro, A (Vall d'Hebron Institut d'Oncologia) ; Remon, J (Vall d'Hebron Institut d'Oncologia) ; Miquel, J M (Vall d'Hebron Institut d'Oncologia) ; Guillaumet-Adkins, A (Universitat Pompeu Fabra) ; Nadal, E (Institut Català d'Oncologia) ; Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ; Arqués, O (Stem Cells and Cancer Group) ; Fasani, R (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Heyn, Holger (Universitat Pompeu Fabra) ; Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ; Palmer, H G (Stem Cells and Cancer Group) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457  
2.
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Élez Fernández, Mª Elena (Universitat Autònoma de Barcelona. Hospital Universitari de la Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina Maqueda, Maria (Vall d'Hebron Institut d'Oncologia) ; Sauri, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autònoma de Barcelona) ; Palmer, Hector G. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
3.
14 p, 4.6 MB A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer / Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ; Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ; Depil, Stephane (Leon Berard Cancer Center (France)) ; Pawitan, Yudi (Karolinska Institutet (Sweden)) ; Martini, Jean-François (Pfizer Oncology Research (USA)) ; Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ; Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ; Kan, Zhengyin (Pfizer Oncology Research (USA)) ; Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ; Kehren, Jeanne (Sanofi (France)) ; Validire, Pierre (Institut Mutualiste Montsouris (France)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ; Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ; Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ; Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ; Onn, Amir (Chaim Sheba Medical Center (Israel)) ; Berger, Raanan (Chaim Sheba Medical Center (Israel)) ; Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ; Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ; Pramesh, CS (Tata Memorial Centre (India)) ; Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ; Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ; Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ; Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ; Morice, Philippe (Gustave-Roussy Cancer Center (France)) ; Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ; Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ; Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ; Hansson, Johan (Karolinska Institutet (Sweden)) ; Berindan-Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Dann, Robert (General Electric Healthcare (USA)) ; Haspel, Joel (Oracle Corporation (UK)) ; Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Laderman, Steve (Agilent Technologies (USA)) ; Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ; Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ; Haywood, Trent (Blue Cross Blue Shield Association (USA)) ; Bresson, Catherine (WIN Consortium (France)) ; Soo, Khee Chee (National Cancer Centre (Singapore)) ; Osman, Iman (New York University Langone Medical Center (USA)) ; Mata, Hilario (MD Anderson Cancer Center (USA)) ; Lee, Jack J. (MD Anderson Cancer Center (USA)) ; Jhaveri, Komal (New York University Langone Medical Center (USA)) ; Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ; Palmer, Gary (Foundation Medicine Inc. (USA)) ; Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ; Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ; Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ; Blay, Jean-Yves (Leon Berard Cancer Center (France)) ; Buller, Richard (Pfizer Oncology Research (USA)) ; Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ; Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ; Mendelsohn, John (MD Anderson Cancer Center (USA)) ; Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ; Rothenberg, Mace (Pfizer Oncology Research (USA)) ; Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ; Ki Hong, Waun (MD Anderson Cancer Center (USA)) ; Kurzrock, Razelle (Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152  
4.
6 p, 2.0 MB Síndrome mieloproliferativo canino de curso agudo / Palmer, G. (Clínica Veterinaria Dr. Palmer (Portals Nous, Mallorca))
Debido a un caso clínico compatible con una leucemia, hemos llegado a la conclusión de que se trata de un síndrome mieloproliferativo según diferentes hemogramas seriados y tinciones citoquímicas de médula ósea.
While studying a clinical case leading to leukemia, we have come the conclusion that its best description is that of myeloproliferative syndrome according to the different studies carried out through blood testing and cytochemical staining of bone marrow sample.

1996
Clínica veterinaria de pequeños animales, Vol. 16, Núm. 1 (Enero-Marzo 1996) , p. 52-57  

See also: similar author names
1 Palmer, Gary
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.